OncoMatch/Clinical Trials/NCT07152288
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Is NCT07152288 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including HSK39297 tablets and HSK39297 tablets for paroxysmal nocturnal hemoglobinuria (pnh).
Treatment: HSK39297 tablets · HSK39297 tablets · HSK39297 tablets — The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HSK39297 in subjects with mild to moderate hepatic impairment and normal hepatic function
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Lab requirements
Blood counts
hemoglobin (Hb) > 70 g/L; platelet level > 30×10⁹/L (except for those judged by the investigator to be in a stable state)
Kidney function
Glomerular filtration rate (eGFR) ≥75 mL/min/1.73m2 calculated using the CKD-EPI formula
Liver function
Child-Pugh classification of Class A or B (without the use of albumin within 14 days), chronic liver injury caused by previous primary liver diseases, including but not limited to non-alcoholic steatohepatitis, viral hepatitis (hepatitis B, hepatitis C), etc.
Glomerular filtration rate (eGFR) ≥75 mL/min/1.73m2 ... hemoglobin (Hb) ≤ 70 g/L; ... platelet level ≤30×10⁹/L ... Child-Pugh classification of Class A or B ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07152288 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify